# OnCo record paper-aryotrust-trastuzumab-pms-2024 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-aryotrust-trastuzumab-pms-2024/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-aryotrust-trastuzumab-pms-2024" ;
  schema:name "Safety evaluation of the trastuzumab biosimilar in Iranian women with HER2-positive breast cancer undergoing adjuvant chemotherapy: a post-marketing surveillance"@en ;
  schema:description "In 597 Iranian women given a locally made copy of trastuzumab after breast cancer surgery, the commonest side effects were reduced heart pumping function, nerve damage and nausea, and the authors judged it generally well tolerated."@en ;
  schema:url <https://onco.cc/key-papers/paper-aryotrust-trastuzumab-pms-2024/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://doi.org/10.1080/14740338.2024.2385483>, <https://pubmed.ncbi.nlm.nih.gov/39076099/> ;
  schema:sameAs <https://doi.org/10.1080/14740338.2024.2385483> ;
  schema:datePublished "2024"^^xsd:gYear ;
  schema:author "Zahedi F, Jafari A, Nasiri Motlagh B, et al." ;
  onco:cancers <https://onco.cc/cancers/breast-her2-positive/> ;
  onco:targets <https://onco.cc/targets/her2/> ;
  onco:drugs <https://onco.cc/drugs/trastuzumab/> ;
  onco:companies <https://onco.cc/companies/aryogen-pharmed/> ;
  onco:terms <https://onco.cc/terms/biosimilar/> ;
  onco:trials <https://onco.cc/trials/nct06021379/> .